The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

More bad news about remicade and enbrel

Over the past few months, I’ve told you about some serious side effects from the prescription drugs Remicade and Enbrel, which are both used to treat rheumatoid arthritis (RA) and Crohn’s disease. In the November 1st e-Alert, I told you how some doctors had been warned about Remicade’s link to tuberculosis, infections, and complications in patients with congestive heart failure. Then on January 2nd, I wrote about Enbrel’s association with central nervous system disorders like MS and Guillian-Barre syndrome.

Unfortunately, the news gets even worse.

Now, research is showing that BOTH drugs may actually cause nerve damage that can lead to MS and other central nervous system (CNS) disorders. And, according to a Reuters Health article, even mainstream authorities are starting to question how these drugs are prescribed.
Drugs can cause a lot of damage in a short period of time

Doctors at Georgetown University Medical Center in Washington, D.C., initiated the research after they encountered a rheumatoid arthritis patient who was suddenly experiencing confusion and having difficulty walking. According to the Reuters article, a brain biopsy revealed demyelation, or damage to the protective sheaths that coat nerve fibers. Searching for an explanation, the doctors noted that the patient had been taking Enbrel for four months. When they searched the FDA Adverse Reports database, they found 19 other reports of patients taking Enbrel or Remicade who had developed symptoms indicative of nerve damage. Eighteen of them had brain MRI’s that showed demyelination. And on average, the patients had been taking the drugs for only five months.

Fortunately all of the patients saw their symptoms at least partially recede once they stopped taking the drugs. But some of them could have been spared the experience all together – if their doctors had been aware that they shouldn’t have been taking the drugs because of pre-existing conditions.

You see, at least four of the 20 patients were known to have MS or a similar CNS syndrome BEFORE they were prescribed the drug. And according to the Reuters Health article, the manufacturers of Enbrel and Remicade have known about this side effect for over a year, and a warning appears on the drugs’ packaging and on the companies’ web sites.
Is it safe for anyone to take these drugs?

The Georgetown researchers concluded “Consideration should be given to avoiding anti-TNFalpha therapy [the drug class that includes Enbrel and Remicade] in patients with pre-existing multiple sclerosis and to discontinuingtherapy immediately when new neurologic signs and symptoms occur”

That seems like the understatement of the year. And I’m not the only one who thinks so. In the Reuters article, Dr. John H. Klippel, medical director of the Arthritis Foundation, states a similar view. Asked to react to the study’s conclusion, Klippel said, “I would be a little more emphatic. Instead of giving ‘consideration to avoiding,’ I think the medical community would be of the view that these drugs should not be used in people with known demyelinating diseases like multiple sclerosis.”

I agree with Klippel. But perhaps I’d be even more emphatic. Only four of the 20 known patients who suffered neurological damage had pre-existing CNS conditions like MS. Even if their doctors had known better, that still leaves at least 16 people who now have permanent damage done to the nerves in their brain – and possibly, an increased risk of developing MS or a similar condition in the future. And who’s to say what the real numbers are; as the Georgetown researchers wrote, “underreporting of adverse events occurs.” (There’s another entry for understatement of the year.)
Adding up the risks – and considering alternatives

To be fair, tens of thousands of people have taken Enbrel and Remicade since their introduction. At this point, we know of only 20 cases where the drugs were associated with demyelinating damage. Anyway you look at it, the risk for the average patient is probably quite small.

But that’s the same thing they said about Remicade’s association with infections, TB, and congestive heart failure, and Enbrel’s earlier association with demyelination. When you start combining all these small risks, sooner or later they get to be too big.

If you take Enbrel or Remicade, discuss these risks with your doctor. Remember, everyone should have a TB test before using these drugs, and people with congestive heart failure or conditions like MS should NOT take them.

And remember that these potentially dangerous prescription drugs are not your only option for treating RA and Crohn’s. As I mentioned in the November 1st e-Alert, we’ve written about the pancreatic enzyme supplement Wobenzyme (February 2001) for RA, and the therapeutic yeast saccharomyces boulardi (SB) (October 2000) for Crohn’s.

Here at HSI, we’ll continue to search for more natural remedies to help you fight RA and Crohn’s. And we’ll keep bringing you the latest information on the side effects of prescription drugs that your doctor may not know about. Having all the facts in front of you is the only way you can make an informed decision about your treatment.

Copyright 1997-2002 by Institute of Health Sciences, L.L.C.

Get a free copy of 5 Household Items that Cause Cancer

By texting HSI to 844-539-1128, you are providing your electronic signature expressly consenting to be called and texted (including by prerecorded messages, using an autodialer, and/or automated means) with alerts, stories, reports, and marketing communications from Institute of Health Sciences, LLC. and its authorized representatives at the phone number you provide, including landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also consent and unconditionally agree to our Privacy Policy and Terms of Use, including the arbitration provision and class action waiver contained therein. Msg&data rates may apply. 15 Msgs/Month. You are not required to agree to this as a condition of making a purchase.

Terms & Conditions

The following Terms and Conditions apply to your use of the website located at hsionline.com (the “website”) and any text messages that you send to or receive from the Institute of Health Sciences, L.L.C. These Terms and Conditions constitute a binding agreement (“Agreement”) between you (“you”) Institute of Health Sciences, L.L.C (“we”, “us”, etc.)  Please read these terms carefully. 

By providing your telephone number to us, texting us a short code listed on the website, or otherwise indicate your agreement to these Terms and Conditions, you are agreeing to the mandatory arbitration provision and class action waiver below. 

ARBITRATION IS MANDATORY AND THE EXCLUSIVE REMEDY FOR ANY AND ALL DISPUTES RELATED TO THIS WEBSITE, THIS AGREEMENT, AND ANY TELEPHONE CALLS, EMAILS, OR TEXT MESSAGES THAT YOU RECEIVE FROM OR ON BEHALF OF US, UNLESS SPECIFIED BELOW OR UNLESS YOU OPT-OUT.

Text Messaging and Telemarketing Terms and Conditions

When you provide your telephone number on this website or send a text message to us with or from a short-code, you agree to receive alerts and communications, and marketing messages including those sent via automated telephone dialing system, text messages, SMS, MMS, and picture messages from Institute of Health Sciences, L.L.C at the phone number you provide on this website or the phone number from which you text the short code, including on landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also agree to the mandatory arbitration provision and class action waiver below. Your consent is not required to purchase goods or services. Message & data rates may apply.

You may opt-out at any time by texting the word STOP to the telephone number from which you receive the text messages.  Call 1-888-213-0764 to learn more.  By providing your telephone number, you agree to notify us of any changes to your telephone number and update your account us to reflect this change. Your carrier may charge you for text messages and telephone calls that you receive, or may prohibit or restrict certain mobile features, and certain mobile features may be incompatible with your carrier or mobile device. Contact your carrier with questions regarding these issues.

Dispute Resolution by Binding Arbitration and Class Action Waiver

Any dispute relating in any way to telephone calls, emails, or text messages that you receive from or on behalf of Institute of Health Sciences, L.L.C this website, or this Agreement (collectively “Disputes”) shall be submitted to confidential arbitration and shall be governed exclusively by the laws of the State of Maryland, excluding its conflict of law provisions.  For the avoidance of doubt, all claims arising under the Telephone Consumer Protection Act and state telemarketing laws shall be considered “Disputes” that are subject to resolution by binding individual, confidential arbitration.

If a Dispute arises under this Agreement, you agree to first contact us at 1-888-213-0764 or help@hsionline.com. Before formally submitting a Dispute to arbitration, you and we may choose to informally resolve the Dispute.  If any Dispute cannot be resolved informally, you agree that any and all Disputes, including the validity of this arbitration clause and class action waiver, shall be submitted to final and binding arbitration before a single arbitrator of the American Arbitration Association (“AAA”) in a location convenient to you or telephonically. Either you or we may commence the arbitration process by submitting a written demand for arbitration with the AAA, and providing a copy to the other party.  The arbitration will be conducted in accordance with the provisions of the AAA’s Commercial Dispute Resolutions Procedures, Supplementary Procedures for Consumer-Related Disputes, in effect at the time of submission of the demand for arbitration.  Except as may be required by law as determined by the arbitrator, no party or arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. Institute of Health Sciences, L.L.C will pay all of the filing costs.  Without limiting the foregoing, YOU EXPRESSLY AGREE TO SUBMIT TO ARBITRATION ALL DISPUTES RELATING TO ANY TEXT MESSAGES OR TELEPHONE CALLS YOU RECEIVE FROM OR ON BEHALF OF US OR ANY ENTITY WITH WHOM WE MAY SHARE YOUR TELEPHONE NUMBER.  Further, we both agree that all entities with whom we share your telephone numbers shall be third party beneficiaries of this Agreement to Arbitrate Disputes, and that those entities have the same rights as Institute of Health Sciences, L.L.C to enforce this arbitration provision.

Notwithstanding the foregoing, the following shall not be subject to arbitration and may be adjudicated only in the state and federal courts of Maryland: (i) any dispute, controversy, or claim relating to or contesting the validity of our or one of our family company’s intellectual property rights and proprietary rights, including without limitation, patents, trademarks, service marks, copyrights, or trade secrets; (ii) an action by us for temporary or preliminary injunctive relief, whether prohibitive or mandatory, or other provisional relief; (iii) any legal action by us against a non-consumer; or (iv) interactions with governmental and regulatory authorities.  You expressly agree to refrain from bringing or joining any claims in any representative or class-wide capacity, including but not limited to bringing or joining any claims in any class action or any class-wide arbitration.

The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. To the fullest extent permitted by applicable law, no arbitration under this Agreement may be joined to an arbitration involving any other party subject to this Agreement, whether through a class action, private attorney general proceeding, class arbitration proceedings or otherwise.

YOU UNDERSTAND THAT YOU WOULD HAVE HAD A RIGHT TO LITIGATE IN A COURT, TO HAVE A JUDGE OR JURY DECIDE YOUR CASE AND TO BE PARTY TO A CLASS OR REPRESENTATIVE ACTION.  HOWEVER, YOU UNDERSTAND AND AGREE TO HAVE ANY CLAIMS DECIDED INDIVIDUALLY AND ONLY THROUGH ARBITRATION.  You shall have thirty (30) days from the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, to opt out of this arbitration agreement, by contacting us by email at help@hsionline.com or by mail Health Sciences Institute, PO Box 913, Frederick, MD 21705-0913. If you do not opt out by the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, then you are not eligible to opt out of this arbitration agreement.

Electronic Signatures

All information communicated on the website is considered an electronic communication.  When you communicate with us through or on the website, by text message or telephone, or via other forms of electronic media, such as e-mail, you are communicating with us electronically.  You agree that we may communicate electronically with you and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

You further acknowledge and agree that by clicking on a button labeled “ORDER NOW”, “SUBMIT”, “I ACCEPT”, “I AGREE”, “YES”, by texting a short code to us in response to a request on this website, or by clicking or similar links or buttons, you are submitting a legally binding electronic signature and are entering into a legally binding contract.  You acknowledge that your electronic submissions constitute your agreement and intent to be bound by this Agreement.  Pursuant to any applicable statutes, regulations, rules, ordinances or other laws, including without limitation the United States Electronic Signatures in Global and National Commerce Act, P.L. 106-229 (the “E-Sign Act”) or other similar statutes, YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS AND OTHER RECORDS AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED THROUGH THE WEBSITE.  Furthermore, you hereby waive any rights or requirements under any statutes, regulations, rules, ordinances or other laws in any jurisdiction which require an original signature, delivery or retention of non-electronic records, or to payments or the granting of credits by other than electronic means You may receive a physical paper copy of this contract by contacting us at help@hsionline.com.

Privacy Policy

Please read our Privacy Policy, which is incorporated herein by reference.  In the event of any conflict between these Terms and Conditions and the Privacy Policy, these Terms shall control.

Contact Us

You may contact us by telephone at 1-888-213-0764 or by email at help@hsionline.com.